RTOG-0839
Terminated
Protocol Information
Tab containing protocol details, study design, and eligibility criteria
Tab containing study documents, informed consent forms, and study materials
Tab containing information for potential study participants
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Principal Investigator
Status
Terminated
Open to Accrual
February 24, 2014
Temporarily Closed to Accrual
June 5, 2015
Closed to Accrual
August 3, 2015
Closed to Accrual & Treatment
October 19, 2015
Complete
June 6, 2017
Terminated
May 20, 2022
Disease Site
Lung [LU] Non-small Cell Lung Cancer
Phase
II
Developmental Therapeutics
No
Primary Objective
Mediastinal nodal clearance following completion of induction chemoradiation +/- panitumumab
Patient Population
Pathologically proven diagnosis Stage IIIA (T1-T3) with a single primary lung parenchymal lesion and N2 positive ipsilateral mediastinal nodes
Data Collection Notice:
Data for this trial is being collected via the NRG/RTOG Data Center.
Target Accrual
97
Protocol Document
Informed Consent
Tracked Amendments
Previous Informed Consents
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.
-
Share this study.
-
-
-
-
